You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD19,CD20,BCMA

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Lymphoblastic Leukemia, Lymphoma, Multiple Myeloma Trial in Taiyuan (CAR-T Autologous T cell injection)

Recruiting
  • Acute Lymphoblastic Leukemia
  • +2 more
  • CAR-T Autologous T cell injection
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Dec 2, 2022

Relapsed/ Refractory Multiple Myeloma Trial (GC012F)

Not yet recruiting
  • Relapsed/ Refractory Multiple Myeloma
  • GC012F
  • (no location specified)
Apr 28, 2023

CAR-T Cell Therapy Trial in Shanghai (GC012F injection)

Recruiting
  • CAR-T Cell Therapy
  • GC012F injection
  • Shanghai, Shanghai, China
    Department of Rheumatology, Ren Ji Hospital South Campus, School
May 5, 2023

CAR-T Trial in Hangzhou (GC012F injection)

Recruiting
  • CAR-T
  • GC012F injection
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital,College of Medicine, Zhejiang Univ
May 10, 2023

Relapsed/Refractory, Systemic Lupus Erythematosus (SLE) Trial in Zhongshan (BCMA-CD19 cCAR T cells)

Recruiting
  • Relapsed/Refractory, Systemic Lupus Erythematosus (SLE)
  • BCMA-CD19 cCAR T cells
  • Zhongshan, Guangdong, China
    Zhongshan People's Hospital
Jul 23, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)

Completed
Has Results
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 3, 2022

Kidney Transplant, Kidney Failure, Highly Sensitized Trial in Boston, New York, Philadelphia (Cyclophosphamide, CART-BCMA,

Not yet recruiting
  • Kidney Transplant
  • +2 more
  • Boston, Massachusetts
  • +2 more
Sep 20, 2023

Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Anti-CD19 and anti-CD20 bicistronic CAR T- cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Apr 10, 2023

POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia Trial in Hangzhou (CD19/BCMA CAR T-cells)

Recruiting
  • POEMS Syndrome
  • +3 more
  • CD19/BCMA CAR T-cells
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Feb 21, 2022

Multiple Myeloma Trial (BCMA CAR T cells, BCMA/CD19 CAR T cells)

Enrolling by invitation
  • Multiple Myeloma
  • BCMA CAR T cells
  • BCMA/CD19 CAR T cells
  • London, County (optional), United Kingdom
    University College London Hospital
Sep 15, 2022

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia

Recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +5 more
  • CAR-20/19-T cells (1 x 10^5 CAR-20/19-T cells/kg)
  • +4 more
  • Milwaukee, Wisconsin
    Medical College of Wisconsin
Sep 22, 2022

Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial

Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +15 more
  • Anti-CD19/CD20/CD22 CAR T-Cells
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 4, 2022

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Chronic Lymphocytic Leukemia Trial in Milwaukee (CAR-20/19-T cells (1.0 x10^5

Completed
Has Results
  • Lymphoma, Non-Hodgkin
  • +3 more
  • CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)
  • +3 more
  • Milwaukee, Wisconsin
    Froedtert Hospital & Medical College of Wisconsin
Jun 26, 2022

B-cell Lymphoma Trial in Sanhe (CD19/CD20 Dual-CAR-T cells)

Completed
  • B-cell Lymphoma
  • CD19/CD20 Dual-CAR-T cells
  • Sanhe, Hebei, China
    Hebei Yanda Ludaopei Hospital
Mar 6, 2022

Advanced Malignancies Trial in Beijing (1A46 Drug Substance)

Not yet recruiting
  • Advanced Malignancies
  • 1A46 Drug Substance
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Aug 4, 2023

B-cell Leukemia Trial in Sanhe (CD19/CD20 Dual-CAR-T cells)

Completed
  • B-cell Leukemia
  • CD19/CD20 Dual-CAR-T cells
  • Sanhe, Hebei, China
    Hebei Yanda Ludaopei Hospital
Mar 6, 2022

B Cell Non-Hodgkin's Lymphoma Trial in Duarte (CD19/CD20-directed CAR-T cells)

Recruiting
  • B Cell Non-Hodgkin's Lymphoma
  • CD19/CD20-directed CAR-T cells
  • Duarte, California
    City of Hope Medical Center
Aug 10, 2022

Scleroderma, Autoimmune Diseases Trial in Hangzhou (Assigned Interventions CD19/BCMA CAR T-cells)

Recruiting
  • Scleroderma
  • Autoimmune Diseases
  • Assigned Interventions CD19/BCMA CAR T-cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of Medicine, Zhejiang Uni
Oct 11, 2021

Sjogren's Syndrome, Autoimmune Diseases Trial in Hangzhou (Assigned Interventions CD19/BCMA CAR T-cells)

Recruiting
  • Sjogren's Syndrome
  • Autoimmune Diseases
  • Assigned Interventions CD19/BCMA CAR T-cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of Medicine, Zhejiang Uni
Oct 11, 2021

Immune Nephritis, Autoimmune Diseases, Lupus Nephritis Trial in Hangzhou (Assigned Interventions CD19/BCMA CAR T-cells)

Recruiting
  • Immune Nephritis
  • +2 more
  • Assigned Interventions CD19/BCMA CAR T-cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of Medicine, Zhejiang Uni
Oct 11, 2021

COVID-19 Infection in Patients Receiving Anti-CD20 Therapy

Active, not recruiting
  • COVID-19
  • +3 more
  • Convalescent Plasma
  • Rochester, Minnesota
    Mayo Clinic
Jul 15, 2022

Acute Lymphocytic Leukemia Trial in Beijing, Tianjin (LCAR-AIO Cells)

Recruiting
  • Acute Lymphocytic Leukemia
  • LCAR-AIO Cells
  • Beijing, Beijing, China
  • +1 more
May 31, 2022

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

B-cell Non-Hodgkin's Lymphoma Trial in Beijing (CD19/CD20 Dual-CAR-T cells)

Suspended
  • B-cell Non-Hodgkin's Lymphoma
  • CD19/CD20 Dual-CAR-T cells
  • Beijing, Beijing, China
    Beijing Tsinghua Changgung Hospital
Jan 29, 2022

Safety and Efficacy Trial in Suzhou (anti-CD19 and anti-BCMA CAR, Immunomodulatory drugs)

Recruiting
  • Safety and Efficacy
  • anti-CD19 and anti-BCMA CAR
  • Immunomodulatory drugs
  • Suzhou, Jiangsu, China
    First Affiliated Hospital, Soochow University
May 17, 2021